KemPharm Inc

NASDAQ:KMPH   1:00:00 PM EDT
4.76
+0.05 (+1.06%)
3:28:46 PM EDT: $4.78 +0.02 (+0.42%)
Products

KemPharm Receives FDA Orphan Drug Designation For Serdexmethylphenidate (SDX) For The Treatment Of Idiopathic Hypersomnia (IH)

Published: 11/18/2022 12:58 GMT
KemPharm Inc (KMPH) - Kempharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (sdx) for the Treatment of Idiopathic Hypersomnia (ih).
Kempharm Inc - Phase 2 Clinical Trial Investigating Kp1077 in Patients With Ih Expected to Initiate Prior to Year-end 2022.
Kempharm Inc - Expects to Initiate a Second Trial in Patients With Narcolepsy in 2023.